Healthcare stocks are slightly higher, with the NYSE Healthcare
Sector Index adding about 0.2% and shares of healthcare companies
in the S&P 500 climbing about 0.3% as a group.
In company news, GTx Inc (
) is down nearly 65% at $1.46 a share, climbing slightly off its
new 52-week low of $1.31 that followed the drug-maker's saying its
Enobosarm drug candidate failed to meet co-primary responder
endpoints during Phase III testing in patients with non-small lung
GTXI said on Monday that the drug failed to improve body mass
and physical function in cancer patients, the latter measured by
improvement in their ability to climb stairs. There currently is no
approved cure for cancer-induced muscle wasting, typically marked
by reduced physical function, fatigue and weight loss.
There was some improvement in lean body mass during one of two
late-stage studies, but GTXI said the drug overall did not meet
pre-specified criteria. The company now is planning for talks with
regulators in the U.S. and Europe to determine its path
In other sector news,
(+) SUPN, (+8.8%) U.S. regulators approve Trokendi XR, an
once-daily extended-release medication for the treatment of
epilepsy. The company expects to have the drug in stores within a
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.